A Study in the United Sates That Looks at the Safety and Effectiveness of Pradaxa Pellets in Children Aged 3 Months to Less Than 12 Years Who Need Treatment of a Blood Clot or Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot
- Conditions
- Venous Thromboembolism
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 6
- Registration Number
- NCT05966740
- Locations
- 🇺🇸
Rady Children's Hospital, San Diego, California, United States
🇺🇸Indiana Hemophilia & Thrombrosis Center, Indianapolis, Indiana, United States
🇺🇸Cincinnati Children's Hospital, Cincinnati, Ohio, United States
A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 1815368 in the Blood
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2023-11-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 14
- Registration Number
- NCT05965583
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer
- Conditions
- Neuroendocrine NeoplasmsSmall Cell Lung Carcinoma (SCLC)
- Interventions
- Drug: [89Zr]Zr-BI 764532
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 12
- Registration Number
- NCT05963867
- Locations
- 🇳🇱
Amsterdam UMC Locatie VUMC, Amsterdam, Netherlands
Oxygen Therapy Use in Patients With Fibrotic Interstitial Lung Disease
- Conditions
- Lung Diseases, Interstitial
- First Posted Date
- 2023-07-24
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 114921
- Registration Number
- NCT05957198
- Locations
- 🇺🇸
Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, United States
A Study in Healthy Men to Test How Different Doses of BI 3000202 Are Tolerated and How Food Influences the Amount of BI 3000202 in the Blood
- First Posted Date
- 2023-07-14
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 68
- Registration Number
- NCT05945888
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 29
- Registration Number
- NCT05934942
- Locations
- 🇩🇪
CRS Clinical Research Services Berlin GmbH, Berlin, Germany
A Study in Healthy Men to Test How Well Different Doses of BI 1839100 Are Tolerated (1490-0003)
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT05934955
- Locations
- 🇯🇵
SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan
A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3
- First Posted Date
- 2023-06-23
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 20
- Registration Number
- NCT05916313
- Locations
- 🇦🇹
Salzburg Cancer Research Institute, Salzburg, Austria
🇩🇪Universitätsklinikum Frankfurt, Frankfurt am Main, Germany
🇩🇪Universitätsklinikum Tübingen, Tübingen, Germany
Natural History of Netherton Syndrome
- Conditions
- Netherton Syndrome
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 12
- Registration Number
- NCT05902663
- Locations
- 🇺🇸
Mission Dermatology Center, Rancho Santa Margarita, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
A Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the Blood
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT05896384
- Locations
- 🇩🇪
Charité Research Organisation GmbH, Berlin, Germany